Biopharmaceutics Classification System and In Vitro-In Vivo Correlation
The biopharmaceutics classification system categorises drug substances into four classes according to their aqueous solubility and intestinal permeability. Class One drugs exhibit high solubility and high permeability and generally show excellent oral bioavailability with dissolution rarely limiting absorption. Class Two drugs exhibit low solubility but high permeability, such that dissolution rate is frequently the rate-limiting step governing oral absorption, making dissolution testing particularly predictive of in vivo performance for this class. Class Three drugs exhibit high solubility but low permeability, with absorption limited by membrane transport rather than dissolution, while Class Four drugs exhibit both low solubility and low permeability and present the greatest formulation and bioavailability challenges.
The Biopharmaceutics Classification System (BCS) is a scientific framework that classifies drug substances based on their aqueous solubility and intestinal permeability. It is widely used in pharmaceutical development to predict oral drug absorption, guide formulation strategies, and support regulatory decisions such as biowaivers.
| BCS Class | Aqueous Solubility | Intestinal Permeability | Key Characteristics | Implications for Drug Absorption | Examples |
|---|---|---|---|---|---|
| Class I | High | High | High solubility and high permeability | Rapid dissolution and absorption; excellent oral bioavailability; dissolution is not rate-limiting | Paracetamol, Metoprolol, Propranolol |
| Class II | Low | High | Low solubility and high permeability | Dissolution is the rate-limiting step; formulation should improve solubility and dissolution | Ibuprofen, Carbamazepine, Ketoconazole |
| Class III | High | Low | High solubility and low permeability | Absorption is limited by membrane permeability rather than dissolution | Atenolol, Cimetidine, Acyclovir |
| Class IV | Low | Low | Low solubility and low permeability | Poor oral bioavailability; greatest formulation challenges requiring advanced drug delivery systems | Hydrochlorothiazide, Furosemide, Paclitaxel |
Solubility refers to the maximum amount of drug that dissolves in an aqueous medium over the physiological pH range (1.2–6.8). According to the BCS, a drug is considered highly soluble if its highest therapeutic dose dissolves in 250 mL or less of aqueous media throughout this pH range.
Permeability describes the extent to which a drug is absorbed through the intestinal membrane. A drug is generally considered highly permeable when 85–90% or more of the administered dose is absorbed after oral administration.
In vitro-in vivo correlation describes a predictive mathematical relationship between an in vitro dissolution property and an in vivo response, most commonly the fraction of drug absorbed, and where established, allows dissolution data to serve as a surrogate for bioequivalence studies, particularly valuable for extended-release formulations undergoing post-approval manufacturing changes. Level A correlation, representing a point-to-point relationship between the entire in vitro dissolution and in vivo absorption profiles, offers the greatest regulatory and biowaiver value, while level B and level C correlations, based on statistical moments or a single dissolution and pharmacokinetic parameter respectively, provide comparatively limited predictive utility.
In Vitro–In Vivo Correlation (IVIVC) is a predictive mathematical relationship between the in vitro dissolution profile of a dosage form and its in vivo absorption or bioavailability. A successful IVIVC enables dissolution testing to serve as a surrogate for in vivo studies.
- Direct relationship between the entire dissolution profile and the in vivo absorption profile.
- Represents the highest level of correlation.
- Most useful for regulatory submissions and biowaivers.
- Compares the mean in vitro dissolution time with the mean in vivo residence or absorption time.
- Provides moderate predictive capability.
- Does not establish a unique point-to-point relationship.
- Relates one dissolution parameter (e.g., percentage dissolved at a specific time) to one pharmacokinetic parameter (e.g., Cmax or AUC).
- Provides limited predictive value.
- Supports formulation development and optimization.
- Assists in product comparison and quality control.
- Facilitates the development of modified-release dosage forms.
- Supports regulatory biowaivers where applicable.
- Reduces the need for repeated in vivo bioequivalence studies.
- Helps establish clinically relevant dissolution specifications.
The Biopharmaceutics Classification System (BCS) plays a vital role in drug development by predicting oral drug absorption based on solubility and permeability characteristics. It guides formulation design, selection of appropriate dissolution methods, and regulatory decisions regarding biowaivers. In Vitro–In Vivo Correlation (IVIVC) further enhances pharmaceutical development by establishing a predictive relationship between dissolution behaviour and in vivo drug performance, thereby reducing development time, minimizing the need for bioequivalence studies, and ensuring consistent product quality and therapeutic efficacy.